A 65-year-old woman with stage IV breast cancer presented because her fingerprints were unrecognizable. She discovered this complication, when she was denied to perform bank transaction because of her fingerprints were unrecognizable (1st image). Patient History For last 3 months, she has undergone treatment for triple-negative breast cancer (lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor type 2 [HER2]) for capecitabine and bevacizumab. During the first cycle, Grade 1 of the hand -foot syndrome (characterized by redness, swelling, and pain on the palms of the hands) was developed and was successfully treated with topical agents.
However, after the third cycle of chemotherapy, the symptoms worsened, with the limitation of self-care activities. Currently, her capecitabine administration is delayed. What could be the underlying cause of loss of…
